First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. (Q55400645)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. (English)

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

0 references

Gregory L Beatty

object named as

Gregory L Beatty

1

0 references

Thomas F. Gajewski

11

object named as

Thomas F Gajewski

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

author name string

Peter J O'Dwyer

2

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

Jason Clark

3

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

Jack G Shi

4

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

Kevin J Bowman

5

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

Peggy A Scherle

6

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

Robert C Newton

7

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

Richard Schaub

8

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

Janet Maleski

9

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

Lance Leopold

10

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

language of work or name

0 references

publication date

4 January 2017

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

Clinical Cancer Research

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

23

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

3269-3276

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

13

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

The future of immune checkpoint therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Immune escape mechanisms as a guide for cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Innate and adaptive immune cells in the tumor microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

IDO activates regulatory T cells and blocks their conversion into Th17-like T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

IDO expression by dendritic cells: tolerance and tryptophan catabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Inhibition of T cell proliferation by macrophage tryptophan catabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Prevention of allogeneic fetal rejection by tryptophan catabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

10 July 2018

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

12 August 2018

IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

12 August 2018

Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5496788

2 November 2018

The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function

1 reference

https://pubmed.ncbi.nlm.nih.gov/28053021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-16-2272

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

1 reference

Europe PubMed Central

6 July 2018

http://europepmc.org/abstract/PMC/5496788

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55400645&oldid=2113049899"